Finally some PR:
https://finance.yahoo.com/news/kazia-provides-overview-paxalisib-related-123000266.html
.
Although not in the same patient population, I'm thinking EVT801 may be as lucrative as Paxalisib, eventually. Yes, yes, I'm a bit premature,
wondering what will be found on the other side of the chasm which, at the moment, seems impossible to cross. The bridge must be made of
dollar bills.